Hepatocellular carcinoma

Hepatocellular carcinoma, or hepatocarcinoma, is the most common type of primary liver cancer and the leading cause of death in patients with liver cirrhosis. 

The disease is two to three times more prevalent in men than in women and develops in over 80% of cases in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or C, alcohol consumption, or fatty liver disease.

Fetge hepatocarcinoma
Authorship: Vall d'Hebron
Creation date: 26.11.2025, 15:43
Modification date: 02.12.2025, 15:59
Share it
Sergi Benavente

Sergi Benavente

Radiation Oncology, General Hospital

Alexandra Giraldo

Alexandra Giraldo

Radiation Oncology, General Hospital

Alexandra Giraldo

Alexandra Giraldo

Radiation Oncology, General Hospital

Sergi Benavente

Sergi Benavente

Radiation Oncology, General Hospital

Xavier Maldonado Pijoan

Xavier Maldonado Pijoan

Radiation Oncology, General Hospital

Cutaneous melanoma

Cutaneous melanoma is a malign tumour located on the skin, usually black or coffee coloured. Some of the main risk factors include exposure to sunlight and freckles. They can develop on any part of the skin, but they are more frequent on men's chests and backs and women's legs. They are responsible for 65% of deaths due to skin cancer. Discovering and treating the illness in time is vital for stopping it spreading to other parts of the body.

Fitxa de malalties melanoma cutani
Authorship: Vall d'Hebron
Creation date: 24.05.2022, 15:08
Modification date: 03.12.2025, 10:35
Share it
Maria Jesus Mañas Garcia

Maria Jesus Mañas Garcia

Radiation Oncology, General Hospital

Prevention of secondary mucositis in antineoplastic therapy

Oral mucositis is the redness or a burning sensation produced by chemotherapy and radiotherapy. It consists of inflammation of the digestive mucous membrane, frequently in mucous membrane in the oral cavity, and may lead to an ulcer, causing pain and/or difficulty eating as well as affecting the quality of life and the patient’s ability to continue with treatment.

Mucositis a Vall d'Hebron
Authorship: Vall d'Hebron
Creation date: 17.12.2021, 10:03
Modification date: 01.02.2022, 18:54
Share it

Subscribe to our newsletters and be a part of Campus Life

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.